Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial
Introduction The PERISCOPE I (Treatment of PERItoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyPErthermic intraperitoneal chemotherapy) study was conducted to investigate the safety and feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cance...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2021-03, Vol.123 (4), p.904-910 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 910 |
|---|---|
| container_issue | 4 |
| container_start_page | 904 |
| container_title | Journal of surgical oncology |
| container_volume | 123 |
| creator | Koemans, Willem J. Kaaij, Rosa T. Wassenaar, Emma C. E. Boerma, Djamila Boot, Henk Sikorska, Karolina Los, Maartje Grootscholten, Cecile Hartemink, Koen J. Veenhof, Alexander A. F. A. Kodach, Liudmila Snaebjornsson, Petur Sandick, Johanna W. |
| description | Introduction
The PERISCOPE I (Treatment of PERItoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyPErthermic intraperitoneal chemotherapy) study was conducted to investigate the safety and feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients with limited peritoneal dissemination. In this study, tumor characteristics and clinical outcome of the patients treated in the PERISCOPE I trial were investigated.
Methods
Patients who had undergone the full study protocol were selected; that is, preoperative systemic chemotherapy, followed by a surgical procedure consisting of a (sub)total gastrectomy, cytoreductive surgery, and HIPEC with oxaliplatin (460 mg/m2) and docetaxel (in escalating doses).
Results
Twenty‐five PERISCOPE I patients underwent the full study protocol. Most patients had an ypT3‐4 tumor (96%) and the diffuse‐type histology was predominant (64%). Seven patients (28%) had a microscopically irradical (R1) resection. In all patients, a complete cytoreduction was achieved. Median follow‐up was 37 (95% confidence interval [CI]: 34–39) months. Disease recurrence was detected in 17 patients (68%). Median disease‐free and overall survival were 12 and 15 months, respectively.
Conclusion
In this series of gastric cancer patients with limited peritoneal dissemination who underwent HIPEC surgery, unfavorable tumor characteristics were common. Survival might be encouraging but disease recurrence was frequent. The efficacy of an HIPEC procedure in improving prognosis is currently being investigated in the PERISCOPE II trial. |
| doi_str_mv | 10.1002/jso.26366 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_journals_2492948525</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2492948525</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-8decfb73d9507632316ffab80a0b44656ea10b29151f6e29b4f8ec6cd666f57d3</originalsourceid><addsrcrecordid>eNqNkVGL1DAUhYso7rj64B-QgC-KdDdN29vmcSmjjizM4q7PJU1vthnaZExSlvlZ_kNTZ1xEEAyBhNzvHA45SfI6oxcZpexy5-0FgxzgSbLKKIeUU14_TVZxxtKi4vQseeH9jlLKORTPk7M8L1hd1bBKftzNk3VEDsIJGdBpH7T0RJieyFEbLcVI7ByknZBYRfaRCNZgfJ0wCB-39svgPt6dlsQ6fa8NCQ5FwJ486DAQQYZDFIYB3RQRbYITfxjJASe7DMX-QPbOSuxnh2RxGZDcrL9ubpvtzZpsoqsW48vkmRKjx1en8zz59nF913xOr7efNs3VdSrzMoe07lGqrsp7XtIKcpZnoJToaipoVxRQAoqMdoxnZaYAGe8KVaME2QOAKqs-P0_eHX1jpO8z-tBO2kscR2HQzr5lRVUxiP9YRvTtX-jOzs7EdJHijBd1yRbq_ZGSznrvULV7pyfhDm1G26XHNvbY_uoxsm9OjnM3Yf9I_i4uAh-OwAN2Vnmp0Uh8xGLTQAEKTpeVRbr-f7rRQQRtTWNnE6L08iTVIx7-Hbn9crs9Zv8J0OLLnQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2492948525</pqid></control><display><type>article</type><title>Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Koemans, Willem J. ; Kaaij, Rosa T. ; Wassenaar, Emma C. E. ; Boerma, Djamila ; Boot, Henk ; Sikorska, Karolina ; Los, Maartje ; Grootscholten, Cecile ; Hartemink, Koen J. ; Veenhof, Alexander A. F. A. ; Kodach, Liudmila ; Snaebjornsson, Petur ; Sandick, Johanna W.</creator><creatorcontrib>Koemans, Willem J. ; Kaaij, Rosa T. ; Wassenaar, Emma C. E. ; Boerma, Djamila ; Boot, Henk ; Sikorska, Karolina ; Los, Maartje ; Grootscholten, Cecile ; Hartemink, Koen J. ; Veenhof, Alexander A. F. A. ; Kodach, Liudmila ; Snaebjornsson, Petur ; Sandick, Johanna W.</creatorcontrib><description>Introduction
The PERISCOPE I (Treatment of PERItoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyPErthermic intraperitoneal chemotherapy) study was conducted to investigate the safety and feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients with limited peritoneal dissemination. In this study, tumor characteristics and clinical outcome of the patients treated in the PERISCOPE I trial were investigated.
Methods
Patients who had undergone the full study protocol were selected; that is, preoperative systemic chemotherapy, followed by a surgical procedure consisting of a (sub)total gastrectomy, cytoreductive surgery, and HIPEC with oxaliplatin (460 mg/m2) and docetaxel (in escalating doses).
Results
Twenty‐five PERISCOPE I patients underwent the full study protocol. Most patients had an ypT3‐4 tumor (96%) and the diffuse‐type histology was predominant (64%). Seven patients (28%) had a microscopically irradical (R1) resection. In all patients, a complete cytoreduction was achieved. Median follow‐up was 37 (95% confidence interval [CI]: 34–39) months. Disease recurrence was detected in 17 patients (68%). Median disease‐free and overall survival were 12 and 15 months, respectively.
Conclusion
In this series of gastric cancer patients with limited peritoneal dissemination who underwent HIPEC surgery, unfavorable tumor characteristics were common. Survival might be encouraging but disease recurrence was frequent. The efficacy of an HIPEC procedure in improving prognosis is currently being investigated in the PERISCOPE II trial.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.26366</identifier><identifier>PMID: 33428786</identifier><language>eng</language><publisher>HOBOKEN: Wiley</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy ; Clinical outcomes ; Combined Modality Therapy ; Cytoreduction Surgical Procedures - mortality ; Docetaxel - administration & dosage ; Female ; Follow-Up Studies ; Gastric cancer ; HIPEC ; Humans ; Hyperthermia, Induced - mortality ; Hyperthermic Intraperitoneal Chemotherapy - mortality ; Life Sciences & Biomedicine ; Male ; Medical prognosis ; Middle Aged ; Oncology ; outcome ; Oxaliplatin - administration & dosage ; pathology ; peritoneal metastasis ; Peritoneal Neoplasms - secondary ; Peritoneal Neoplasms - therapy ; Prognosis ; Science & Technology ; Stomach Neoplasms - pathology ; Stomach Neoplasms - therapy ; Surgery ; survival ; Survival Rate</subject><ispartof>Journal of surgical oncology, 2021-03, Vol.123 (4), p.904-910</ispartof><rights>2021 Wiley Periodicals LLC</rights><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>11</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000606649000001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c3536-8decfb73d9507632316ffab80a0b44656ea10b29151f6e29b4f8ec6cd666f57d3</citedby><cites>FETCH-LOGICAL-c3536-8decfb73d9507632316ffab80a0b44656ea10b29151f6e29b4f8ec6cd666f57d3</cites><orcidid>0000-0003-0101-081X ; 0000-0003-4282-1096</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.26366$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.26366$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,39263,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33428786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koemans, Willem J.</creatorcontrib><creatorcontrib>Kaaij, Rosa T.</creatorcontrib><creatorcontrib>Wassenaar, Emma C. E.</creatorcontrib><creatorcontrib>Boerma, Djamila</creatorcontrib><creatorcontrib>Boot, Henk</creatorcontrib><creatorcontrib>Sikorska, Karolina</creatorcontrib><creatorcontrib>Los, Maartje</creatorcontrib><creatorcontrib>Grootscholten, Cecile</creatorcontrib><creatorcontrib>Hartemink, Koen J.</creatorcontrib><creatorcontrib>Veenhof, Alexander A. F. A.</creatorcontrib><creatorcontrib>Kodach, Liudmila</creatorcontrib><creatorcontrib>Snaebjornsson, Petur</creatorcontrib><creatorcontrib>Sandick, Johanna W.</creatorcontrib><title>Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial</title><title>Journal of surgical oncology</title><addtitle>J SURG ONCOL</addtitle><addtitle>J Surg Oncol</addtitle><description>Introduction
The PERISCOPE I (Treatment of PERItoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyPErthermic intraperitoneal chemotherapy) study was conducted to investigate the safety and feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients with limited peritoneal dissemination. In this study, tumor characteristics and clinical outcome of the patients treated in the PERISCOPE I trial were investigated.
Methods
Patients who had undergone the full study protocol were selected; that is, preoperative systemic chemotherapy, followed by a surgical procedure consisting of a (sub)total gastrectomy, cytoreductive surgery, and HIPEC with oxaliplatin (460 mg/m2) and docetaxel (in escalating doses).
Results
Twenty‐five PERISCOPE I patients underwent the full study protocol. Most patients had an ypT3‐4 tumor (96%) and the diffuse‐type histology was predominant (64%). Seven patients (28%) had a microscopically irradical (R1) resection. In all patients, a complete cytoreduction was achieved. Median follow‐up was 37 (95% confidence interval [CI]: 34–39) months. Disease recurrence was detected in 17 patients (68%). Median disease‐free and overall survival were 12 and 15 months, respectively.
Conclusion
In this series of gastric cancer patients with limited peritoneal dissemination who underwent HIPEC surgery, unfavorable tumor characteristics were common. Survival might be encouraging but disease recurrence was frequent. The efficacy of an HIPEC procedure in improving prognosis is currently being investigated in the PERISCOPE II trial.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Combined Modality Therapy</subject><subject>Cytoreduction Surgical Procedures - mortality</subject><subject>Docetaxel - administration & dosage</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastric cancer</subject><subject>HIPEC</subject><subject>Humans</subject><subject>Hyperthermia, Induced - mortality</subject><subject>Hyperthermic Intraperitoneal Chemotherapy - mortality</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>outcome</subject><subject>Oxaliplatin - administration & dosage</subject><subject>pathology</subject><subject>peritoneal metastasis</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Peritoneal Neoplasms - therapy</subject><subject>Prognosis</subject><subject>Science & Technology</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - therapy</subject><subject>Surgery</subject><subject>survival</subject><subject>Survival Rate</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><recordid>eNqNkVGL1DAUhYso7rj64B-QgC-KdDdN29vmcSmjjizM4q7PJU1vthnaZExSlvlZ_kNTZ1xEEAyBhNzvHA45SfI6oxcZpexy5-0FgxzgSbLKKIeUU14_TVZxxtKi4vQseeH9jlLKORTPk7M8L1hd1bBKftzNk3VEDsIJGdBpH7T0RJieyFEbLcVI7ByknZBYRfaRCNZgfJ0wCB-39svgPt6dlsQ6fa8NCQ5FwJ486DAQQYZDFIYB3RQRbYITfxjJASe7DMX-QPbOSuxnh2RxGZDcrL9ubpvtzZpsoqsW48vkmRKjx1en8zz59nF913xOr7efNs3VdSrzMoe07lGqrsp7XtIKcpZnoJToaipoVxRQAoqMdoxnZaYAGe8KVaME2QOAKqs-P0_eHX1jpO8z-tBO2kscR2HQzr5lRVUxiP9YRvTtX-jOzs7EdJHijBd1yRbq_ZGSznrvULV7pyfhDm1G26XHNvbY_uoxsm9OjnM3Yf9I_i4uAh-OwAN2Vnmp0Uh8xGLTQAEKTpeVRbr-f7rRQQRtTWNnE6L08iTVIx7-Hbn9crs9Zv8J0OLLnQ</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Koemans, Willem J.</creator><creator>Kaaij, Rosa T.</creator><creator>Wassenaar, Emma C. E.</creator><creator>Boerma, Djamila</creator><creator>Boot, Henk</creator><creator>Sikorska, Karolina</creator><creator>Los, Maartje</creator><creator>Grootscholten, Cecile</creator><creator>Hartemink, Koen J.</creator><creator>Veenhof, Alexander A. F. A.</creator><creator>Kodach, Liudmila</creator><creator>Snaebjornsson, Petur</creator><creator>Sandick, Johanna W.</creator><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0101-081X</orcidid><orcidid>https://orcid.org/0000-0003-4282-1096</orcidid></search><sort><creationdate>20210301</creationdate><title>Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial</title><author>Koemans, Willem J. ; Kaaij, Rosa T. ; Wassenaar, Emma C. E. ; Boerma, Djamila ; Boot, Henk ; Sikorska, Karolina ; Los, Maartje ; Grootscholten, Cecile ; Hartemink, Koen J. ; Veenhof, Alexander A. F. A. ; Kodach, Liudmila ; Snaebjornsson, Petur ; Sandick, Johanna W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-8decfb73d9507632316ffab80a0b44656ea10b29151f6e29b4f8ec6cd666f57d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Combined Modality Therapy</topic><topic>Cytoreduction Surgical Procedures - mortality</topic><topic>Docetaxel - administration & dosage</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastric cancer</topic><topic>HIPEC</topic><topic>Humans</topic><topic>Hyperthermia, Induced - mortality</topic><topic>Hyperthermic Intraperitoneal Chemotherapy - mortality</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>outcome</topic><topic>Oxaliplatin - administration & dosage</topic><topic>pathology</topic><topic>peritoneal metastasis</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Peritoneal Neoplasms - therapy</topic><topic>Prognosis</topic><topic>Science & Technology</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - therapy</topic><topic>Surgery</topic><topic>survival</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koemans, Willem J.</creatorcontrib><creatorcontrib>Kaaij, Rosa T.</creatorcontrib><creatorcontrib>Wassenaar, Emma C. E.</creatorcontrib><creatorcontrib>Boerma, Djamila</creatorcontrib><creatorcontrib>Boot, Henk</creatorcontrib><creatorcontrib>Sikorska, Karolina</creatorcontrib><creatorcontrib>Los, Maartje</creatorcontrib><creatorcontrib>Grootscholten, Cecile</creatorcontrib><creatorcontrib>Hartemink, Koen J.</creatorcontrib><creatorcontrib>Veenhof, Alexander A. F. A.</creatorcontrib><creatorcontrib>Kodach, Liudmila</creatorcontrib><creatorcontrib>Snaebjornsson, Petur</creatorcontrib><creatorcontrib>Sandick, Johanna W.</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koemans, Willem J.</au><au>Kaaij, Rosa T.</au><au>Wassenaar, Emma C. E.</au><au>Boerma, Djamila</au><au>Boot, Henk</au><au>Sikorska, Karolina</au><au>Los, Maartje</au><au>Grootscholten, Cecile</au><au>Hartemink, Koen J.</au><au>Veenhof, Alexander A. F. A.</au><au>Kodach, Liudmila</au><au>Snaebjornsson, Petur</au><au>Sandick, Johanna W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial</atitle><jtitle>Journal of surgical oncology</jtitle><stitle>J SURG ONCOL</stitle><addtitle>J Surg Oncol</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>123</volume><issue>4</issue><spage>904</spage><epage>910</epage><pages>904-910</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Introduction
The PERISCOPE I (Treatment of PERItoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyPErthermic intraperitoneal chemotherapy) study was conducted to investigate the safety and feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients with limited peritoneal dissemination. In this study, tumor characteristics and clinical outcome of the patients treated in the PERISCOPE I trial were investigated.
Methods
Patients who had undergone the full study protocol were selected; that is, preoperative systemic chemotherapy, followed by a surgical procedure consisting of a (sub)total gastrectomy, cytoreductive surgery, and HIPEC with oxaliplatin (460 mg/m2) and docetaxel (in escalating doses).
Results
Twenty‐five PERISCOPE I patients underwent the full study protocol. Most patients had an ypT3‐4 tumor (96%) and the diffuse‐type histology was predominant (64%). Seven patients (28%) had a microscopically irradical (R1) resection. In all patients, a complete cytoreduction was achieved. Median follow‐up was 37 (95% confidence interval [CI]: 34–39) months. Disease recurrence was detected in 17 patients (68%). Median disease‐free and overall survival were 12 and 15 months, respectively.
Conclusion
In this series of gastric cancer patients with limited peritoneal dissemination who underwent HIPEC surgery, unfavorable tumor characteristics were common. Survival might be encouraging but disease recurrence was frequent. The efficacy of an HIPEC procedure in improving prognosis is currently being investigated in the PERISCOPE II trial.</abstract><cop>HOBOKEN</cop><pub>Wiley</pub><pmid>33428786</pmid><doi>10.1002/jso.26366</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0101-081X</orcidid><orcidid>https://orcid.org/0000-0003-4282-1096</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2021-03, Vol.123 (4), p.904-910 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_journals_2492948525 |
| source | MEDLINE; Access via Wiley Online Library; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy Clinical outcomes Combined Modality Therapy Cytoreduction Surgical Procedures - mortality Docetaxel - administration & dosage Female Follow-Up Studies Gastric cancer HIPEC Humans Hyperthermia, Induced - mortality Hyperthermic Intraperitoneal Chemotherapy - mortality Life Sciences & Biomedicine Male Medical prognosis Middle Aged Oncology outcome Oxaliplatin - administration & dosage pathology peritoneal metastasis Peritoneal Neoplasms - secondary Peritoneal Neoplasms - therapy Prognosis Science & Technology Stomach Neoplasms - pathology Stomach Neoplasms - therapy Surgery survival Survival Rate |
| title | Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T07%3A21%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20characteristics%20and%20clinical%20outcome%20of%20peritoneal%20metastasis%20of%20gastric%20origin%20treated%20with%20a%20hyperthermic%20intraperitoneal%20chemotherapy%20procedure%20in%20the%20PERISCOPE%20I%20trial&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Koemans,%20Willem%C2%A0J.&rft.date=2021-03-01&rft.volume=123&rft.issue=4&rft.spage=904&rft.epage=910&rft.pages=904-910&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.26366&rft_dat=%3Cproquest_webof%3E2492948525%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2492948525&rft_id=info:pmid/33428786&rfr_iscdi=true |